Genetic Variability for Downy Mildew Disease Incidence in Mapping Population Parents of Pearl Millet

Downy mildew caused by Sclerospora graminicola (Sacc.) Shroet. is a major biotic constraint to pearl millet production in the semi-arid tropics. The pathogen is heterothallic and frequent recombination leads to evolution of new virulent populations. Identification of resistance to new virulent isolates is a prerequisite for resistance breeding. In the present investigation, forty parents along with five control entries were screened against three Indian populations of Sclerospora graminicola under greenhouse conditions. Among the parental lines under study, ICMP 85410-P7, LGD-1-B-10, Tift 23DB-P1-P5, H77/833-2-P5, H77/833-2, Tift 238D1, ICMB 89111-P6, 81B-P13, ICMB 01222-P1, ICMB 95333-P1, ICMB 95333-P5 and IPC 804-P4 were found to be highly susceptible (>80 % DMI) in screening against three Indigenous pathogen isolates from Gujarat (Sg445), Haryana (Sg519) and Rajasthan (Sg526), while 863B-P2, AIMP 92901-S1-183-2-2-B-P08 and AIMP 92901-S1-15-1-2-B-P03 were resistant (<10% DMI) to test isolates. Some parents exhibited different levels of DM incidence to pathogen - isolates

Enabling precision medicine via standard communication of HTS provenance, analysis, and results

<div><p>A personalized approach based on a patient's or pathogen’s unique genomic sequence is the foundation of precision medicine. Genomic findings must be robust and reproducible, and experimental data capture should adhere to findable, accessible, interoperable, and reusable (FAIR) guiding principles. Moreover, effective precision medicine requires standardized reporting that extends beyond wet-lab procedures to computational methods. The BioCompute framework (<a href="https://w3id.org/biocompute/1.3.0" target="_blank">https://w3id.org/biocompute/1.3.0</a>) enables standardized reporting of genomic sequence data provenance, including provenance domain, usability domain, execution domain, verification kit, and error domain. This framework facilitates communication and promotes interoperability. Bioinformatics computation instances that employ the BioCompute framework are easily relayed, repeated if needed, and compared by scientists, regulators, test developers, and clinicians. Easing the burden of performing the aforementioned tasks greatly extends the range of practical application. Large clinical trials, precision medicine, and regulatory submissions require a set of agreed upon standards that ensures efficient communication and documentation of genomic analyses. The BioCompute paradigm and the resulting BioCompute Objects (BCOs) offer that standard and are freely accessible as a GitHub organization (<a href="https://github.com/biocompute-objects" target="_blank">https://github.com/biocompute-objects</a>) following the “Open-Stand.org principles for collaborative open standards development.” With high-throughput sequencing (HTS) studies communicated using a BCO, regulatory agencies (e.g., Food and Drug Administration [FDA]), diagnostic test developers, researchers, and clinicians can expand collaboration to drive innovation in precision medicine, potentially decreasing the time and cost associated with next-generation sequencing workflow exchange, reporting, and regulatory reviews.</p></div